ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells
Priyanka Verma, Yeqiao Zhou, Zhendong Cao, Peter V Deraska, Moniher Deb, Eri Arai, Weihua Li, Yue Shao, Laura Puentes, Yiwen Li, Sonali Patankar, Robert H Mach, Robert B Faryabi, Junwei Shi, Roger A Greenberg. Nat Cell Biol. 2021 Jan 18. doi: 10.1038/s41556-020-00624-3. Online ahead of print.
Summary
PARP inhibitors are recently developed drugs that have shown great promise against some types of ovarian, breast, prostate and pancreatic cancer, but many patients’ tumors develop resistance to the drugs. Now researchers at the Perelman School of Medicine at the University of Pennsylvania have reported a strategy for defeating such resistance and boosting the effectiveness of these drugs.
Read the Penn Medicine news release
